ArticleWorld journal of microbiology & biotechnology2025
Antimicrobial activities and beta-lactamase inhibitory property of actinomycetes from Atlas forest soils in Northeastern Algeria.
Article in World journal of microbiology & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Actinomycetes bacteria are an inexhaustible natural source of secondary metabolites with diverse antimicrobial activities. In the current study, screening based on antimicrobial activity of the cell-free supernatant (CFS) of 23 actinomycetes isolates from Atlas forest soils in Northeastern Algeria was performed against ten human bacterial pathogens and Candida albicans ATCC 10231 strain. Among them, three isolates AM138DZ, AM141DZ and AM183DZ showed antagonistic effects towards indicator pathogens. The isolate AM183AZ exhibited strong activities against Staphylococcus aureus ATCC 6538, C. albicans ATCC 10231, clinical strains Esherichia coli BLSE and Salmonella spp. BLSE. The isolates AM141AZ and AM138AZ displayed high antimicrobial activity towards C. albicans 10231. Interestingly, the CFS of AM138DZ and AM141DZ combined with amoxicillin inhibited β-lactamase activity from Klebsiella pneumoniae ATCC 700603, an extended-spectrum β-lactamase producing strain. The ethyl acetate extracts of the three isolates displayed a large spectrum of antimicrobial activity against all pathogens tested. Analysis of their contents by UPLC-ESI-MS/MS revealed the identification of 16 to 18 compounds, among them 5 flavonoids, 6 organic acids and 2 phenols. Overall, flavonoids (such as rutin, chrysin, quercetin and catechin) were the major compounds detected in the three extracts. Depending on the isolate, other notable compounds were detected at significant levels: β-caroten, salicin and salycilic acid. Molecular identification of the three isolates using 16S rRNA sequence homology suggested that these isolates should be assigned as Streptomyces flavogriseus AM138DZ, Streptomyces felleus AM141DZ, and Streptomyces rubiginosohelvolus AM183DZ strains. Our study provides a promising natural alternative source of antimicrobials and β-lactamase inhibitors in particular.
Indexed as
Identifiers
40232350What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.